Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Headlines > UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug
    Headlines

    UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

    Published by Global Banking & Finance Review®

    Posted on October 16, 2025

    2 min read

    Last updated: January 21, 2026

    UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:recommendationsNHShealthcare

    Quick Summary

    NICE approves GSK's Apretude for HIV prevention, allowing NHS access in England and Wales. The drug offers an alternative to oral medications.

    UK's NICE Endorses ViiV Healthcare's HIV Prevention Drug Apretude

    (Reuters) -The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wales, the GSK unit said on Friday.

    The country's drug regulator had approved ViiV's injection, Apretude, last year for prevention of HIV-1 in adults and young people who weigh at least 35 kilograms and are at high risk of acquiring the infection.

    A positive recommendation from the National Institute for Health and Care Excellence, or NICE, solidifies the final guidance related to Apretude for National Health Service, ViiV said.

    It also allows the drug to be routinely funded and enables access through NHS. Pending any appeals, the drug will be available to eligible people in Wales within two months and in England within three months.

    Such preventative treatments, medically called pre-exposure prophylaxis or PrEP, are used to reduce the risk of acquiring HIV.

    Apretude provides an alternative for people who cannot, or prefer not to, take oral HIV-prevention medication. It won U.S. approval in late 2021 and in Europe in 2023, and generated 279 million pounds ($374.95 million) in global sales last year.

    The drug competes with U.S. drugmaker Gilead's oral daily pills Truvada and Descovy along with long-acting injectable drug Yeztugo.

    ViiV's drug can be given every two months, compared with Gilead's Yeztugo, which is given every six months. GSK is exploring a long acting version of Apretude that could potentially be dosed every four months or more.

    ($1 = 0.7441 pounds)

    (Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)

    Key Takeaways

    • •NICE endorses GSK's Apretude for HIV prevention.
    • •Apretude is available via NHS in England and Wales.
    • •The drug offers an alternative to oral HIV prevention meds.
    • •Apretude competes with Gilead's Truvada and Descovy.
    • •GSK explores a longer-acting version of Apretude.

    Frequently Asked Questions about UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

    1What is HIV?

    HIV, or Human Immunodeficiency Virus, is a virus that attacks the immune system, making it difficult for the body to fight infections and diseases.

    More from Headlines

    Explore more articles in the Headlines category

    Image for US wants Russia, Ukraine to end war by summer, Zelenskiy says
    US wants Russia, Ukraine to end war by summer, Zelenskiy says
    Image for Russia to interrogate two suspects over attempted killing of general, report says
    Russia to interrogate two suspects over attempted killing of general, report says
    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Ukraine backs Pope's call for Olympic truce in war with Russia
    Ukraine backs Pope's call for Olympic truce in war with Russia
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Not Italy's Devil's Island: Sardinia bristles at mafia inmate plan
    Not Italy's Devil's Island: Sardinia bristles at mafia inmate plan
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for Exclusive-US plans initial payment towards billions owed to UN-envoy Waltz
    Exclusive-US plans initial payment towards billions owed to UN-envoy Waltz
    Image for Trump says good talks ongoing on Ukraine
    Trump says good talks ongoing on Ukraine
    Image for France to rally aid for Lebanon as it warns truce gains remain fragile
    France to rally aid for Lebanon as it warns truce gains remain fragile
    Image for Exclusive-US aims for March peace deal in Ukraine, quick elections, sources say
    Exclusive-US aims for March peace deal in Ukraine, quick elections, sources say
    View All Headlines Posts
    Previous Headlines PostSinger Sam Fender wins Mercury Prize for album 'People Watching'
    Next Headlines PostTrump, Merck KGaA announce deal to cut some IVF drug prices